@Article{biocell.2022.016225, AUTHOR = {SHUTING GU, JINGYI QIN, SAINAN GAO, ZHEN WANG,4, QI MENG,4, YAN LI,4, BING LU, SONGLIN ZHOU,2, YUNZHAO XU,6}, TITLE = {KIAA1199 induces advanced biological behavior and development of ovarian cancer through activation of the IL-6/STAT3 pathway}, JOURNAL = {BIOCELL}, VOLUME = {46}, YEAR = {2022}, NUMBER = {3}, PAGES = {689--697}, URL = {http://www.techscience.com/biocell/v46n3/45620}, ISSN = {1667-5746}, ABSTRACT = {Recently, abnormal expression of KIAA1199 has been detected in Epithelial Ovarian Cancer (EOC). However, the underlined anti-ovarian cancer mechanism of KIAA1199 remains to be enlightened. In our study, we performed to elucidate the effects of KIAA1199 on the advanced biological behavior of EOC cells through activation of the IL-6/STAT3 pathway. Confirmed by immunohistochemistry, KIAA1199 was highly expressed in ovarian borderline and malignant epithelial tumors. A retrospective analysis found that EOC patients with low expression of KIAA1199 had a significantly higher 5-year survival rate than those with high expression. Mechanistically, IL-6 was used to stimulate EOC cells, and the expression of KIAA1199, STAT3 and p-STAT3 increased after IL-6 stimulation. These results could show that KIAA1199 is transcriptionally activated by IL6/STAT3 pathway, thereby accelerating the deterioration of EOC. KIAA1199 could also be used as a poor prognosis factor and potential target in treatment.}, DOI = {10.32604/biocell.2022.016225} }